Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia

(November 22, 2017)

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia... Continue Reading

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor

(November 20, 2017)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary... Continue Reading

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

(November 15, 2017)

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies... Continue Reading

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer

(November 14, 2017)

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically... Continue Reading

Jackson Oncology Associates, PLLC
The Hederman Cancer Center
1227 North State Street, Suite 101
Jackson, MS 39202
TEL: (601)355-2485
FAX: (601)353-1463
Click Here for Map

Jackson Oncology Associates, PLLC
2368 Grove Street
Vicksburg, MS 39180
TEL: (601)638-3447
FAX: (601)630-9227
Click Here for Map
Jackson Oncology Associates, PLLC
St. Dominic Cancer Center
2969 Curran Drive North, Suite 200
TEL: (601)974-5600
FAX: (601)974-5699
Click Here for Map

Jackson Oncology Associates, PLLC
King's Daughters Hospital
427 Highway 51 North
Brookhaven, MS 39601
TEL: (601)355-2495
Click Here for Map